There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Better Therapeutics, Inc. (BTTX – Research Report) with bullish sentiments.
Lantheus (LNTH)
B.Riley Financial analyst Yuan Zhi reiterated a Buy rating on Lantheus today and set a price target of $102.00. The company’s shares closed last Friday at $53.31.
According to TipRanks.com, Zhi has 0 stars on 0-5 stars ranking scale with an average return of
Lantheus has an analyst consensus of Strong Buy, with a price target consensus of $107.75, implying a 100.6% upside from current levels. In a report issued on December 6, Mizuho Securities also maintained a Buy rating on the stock with a $105.00 price target.
See today’s best-performing stocks on TipRanks >>
Better Therapeutics, Inc. (BTTX)
Chardan Capital analyst Keay Nakae maintained a Buy rating on Better Therapeutics, Inc. today and set a price target of $14.00. The company’s shares closed last Friday at $1.49, close to its 52-week low of $0.91.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Better Therapeutics, Inc. with a $14.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LNTH:
- Lantheus announces pricing of offering of $500M convertible senior notes
- Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
- Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
- Lantheus announces proposed offering of $500M convertible senior notes
- Lantheus appoints Amanda Morgan SVP, commercial
